Navigation Links
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Date:8/19/2007

TARRYTOWN, N.Y., Aug. 17 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that it has entered into agreements to sell 2.0 million shares of common stock and warrants to purchase 0.4 million shares of common stock, at a purchase price of $3.785 per unit. The five-year warrants will be exercisable at any time after the six month anniversary of issuance at an exercise price of $3.948 per share.

The securities in this transaction were offered by Emisphere pursuant to an effective shelf registration statement and a registration statement filed pursuant to Rule 462(b) promulgated under the Securities Act of 1933, as amended.

ThinkEquity Partners LLC acted as sole placement agent, and WBB Securities LLC acted as financial consultant. Proceeds from the offering will be used by Emisphere for general corporate purposes, including further development of its lead clinical programs. The transaction is expected to close on or about August 22, 2007, subject to the satisfaction of customary closing conditions.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor will there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

The offer is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. When available, a final prospectus can be obtained from Emisphere Technologies, Inc., 765 Old Saw Mill River Road, Tarrytown, New York 10591; telephone, (914) 785-4717 or from the U.S. Securities
'/>"/>

SOURCE Emisphere Technologies, Inc.

Copyright©2007 PR Newswire.

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 PAREXEL International Corporation ... clinical research organization , announced today that ... to acquire all of the business assets of ... provider of specialized pharmacovigilance services, based in ... detection, assessment, monitoring, and prevention of adverse ...
(Date:3/26/2015)... America," the popular news television program that airs in numerous ... film actor James Earl Jones, has announced that it will ... , Botany is commonly described as the scientific study of ... more complicated than that. Scientists and other professionals study a ... smallest bacteria known to man to the largest trees that ...
(Date:3/26/2015)... WriteResult, a premier provider of ePRO technologies and ... of Public Health and New Haven Farms to capture ... project. The goal of the study was to evaluate ... access to fresh produce and nutrition education on food ... blood pressure, diabetes and weight gain. Patients completed an ...
(Date:3/25/2015)... 2015 Agnition announced today that it ... Farmer, airing for the first time at 7:30 a.m. ... Farmer will explore the extremely important role soil microbes ... a patented Microbial Catalyst™ technology that enhances soil and ... segment will air again on April 28. , A ...
Breaking Biology Technology:PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2
... SAN FRANCISCO, Calif., Dec. 8 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... and chief executive officer, will participate in a panel,discussion at ... Drugs and Targets for Inflammation and Rheumatology", will take,place on ... Westin Times,Square Hotel in New York City. , ...
... endpoint of non-inferiority to Pegasys (peginterferon alfa-2a) in the ACHIEVE ... hepatitis C - , , ... serious adverse events, severe adverse events and discontinuations due to ... , ROCKVILLE, Md., Dec. 8 Human Genome ...
... ATSI ), manufacturer and marketer of state-of-the-art cardiac surgery,products and ... of the ATS 3f(R) Aortic Bioprosthesis that includes a new ... , (Logo: ... the ATS 3f Aortic Bioprosthesis PMA was approved on October ...
Cached Biology Technology:Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 2Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 3Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 4Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 5Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 6Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 7Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 8Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 9ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 2ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 3
(Date:3/12/2015)... VIEW, Calif. , March 12, 2015 /PRNewswire/ ... with Complimentary Registration here: http://bit.ly/1G7Os0L . SPEAKERS: ... Manager Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... in order to compete in several different markets ... market is currently witnessing an uptrend. ...
(Date:3/10/2015)... -- Transforming How We Look at Medicine ... Human Space Flight" by Michael A. Schmidt ... was recently featured by Springer Science Media, highlighting the most ... Specifically, "Personalized Medicine in Human Space Flight" was among ... and 2014 from Springer in the journal Metabolomics ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
Breaking Biology News(10 mins):Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3
... Researchers are delving into abnormal gene function in mitochondria, ... the place where energy is generated from the most ... to life, defects in mitochondria may affect a wide ... Some names of mitochondrial disorders are Leigh,s disease, ...
... research, published this week in Chemical Communications , ... insects, ability to detect plants by interfering with their ... by insect pests and contribute to food security. ... institute of BBSRC said: "One way in which insects ...
... that a University of Utah cardiologist proposes as a cause ... National Institutes of Health (NIH) likes to seeand reward with ... Pioneer Award. Ivor J. Benjamin, M.D., professor of internal ... of Cardiovascular Research at the U of U School of ...
Cached Biology News:How mitochondrial gene defects impair respiration, other major life functions 2How mitochondrial gene defects impair respiration, other major life functions 3Scientists discover how to send insects off the scent of crops 2Groundbreaking model of heart disease rewarded with NIH Pioneer Award 2Groundbreaking model of heart disease rewarded with NIH Pioneer Award 3
Anti 7H6 Antigen (tight-junction associated protein Antigen) Monoclonal Antibody 7H6...
... Rabbit Antibody to ARG. Vasopressin ... vasopression peptide. Cells are found in ... fibers are found throughout the hypothalmus ... perfused tissue. Immunogen: ...
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Biology Products: